Series A Financing for Mnemosyne Pharmaceuticals

In 2012, Providence-based Mnemosyne Pharmaceuticals, Inc. announced that it will raise $5,384,496 in its round of equity funding.  We represented, the company in the issuance of series A convertible preferred stock to the investors pursuant to Regulation D of the Securities Act.  The round was led by Access BridgeGap Ventures and included returning investor Slater Technology Fund.
Posted on February 1, 2012

RELATED PROFESSIONALS
RELATED SERVICES
INDUSTRIES